Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
Completed
Abbott
Phase 3
2002-02-01
The objective of this study is to determine whether paricalcitol is safe and effective
compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney
disease.
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
Completed
Abbott
Phase 3
2002-02-01
The objective of this study is to determine whether paricalcitol is safe and effective
compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney
disease.
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
Completed
Abbott
Phase 3
2002-02-01
The objective of this study is to determine whether paricalcitol is safe and effective
compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney
disease.
A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects
Completed
Abbott
Phase 2
2002-01-01
A study to determine the effect of Zemplar on the regulation of serum calcium levels and the
need for administration of elemental calcium in hypocalcemic intensive care patients
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
Completed
Abbott
Phase 4
2002-01-01
The purpose of this study is to see if Zemplar, a vitamin D medication, safely and
effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
Terminated
Abbott
Phase 4
2003-04-01
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for
the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney
disease on hemodialysis as measured by time to death.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
